Alpa Laboratories appoints Diksha Jaswani as company secretary
- Alpa Laboratories appoints Ms. Diksha Jaswani as Company Secretary cum Compliance Officer
- The appointment takes effect from September 17, 2026, following Board approval
- Ms. Jaswani holds Membership No. A80495 with the Institute of Company Secretaries of India
- She has no shareholding in the company and no disclosed relationships with directors

*this image is generated using AI for illustrative purposes only.
Alpa Laboratories Limited appointed Ms. Diksha Jaswani as its Company Secretary cum Compliance Officer effective September 17, 2026. The Board of Directors approved the move during a meeting held on the same date.
The appointment was made based on recommendations from the Nomination and Remuneration Committee. It complies with Regulation 6(1) and Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III.
Appointment Details
Ms. Jaswani holds Membership No. A80495 with the Institute of Company Secretaries of India. She is an associate member with extensive experience in company law, including ROC filings and annual regulatory processes.
| Particulars | Details |
|---|---|
| Name | Ms. Diksha Jaswani |
| Designation | Company Secretary cum Compliance Officer (KMP) |
| Date of Appointment | September 17, 2026 |
| Shareholding | Nil |
| Relationship with Directors | Not Applicable |
The company disclosed that Ms. Jaswani holds no shares in Alpa Laboratories. There are no disclosed relationships between her and the existing directors. The term of appointment is listed as not applicable in the filing.
Historical Stock Returns for Alpa Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.42% | -5.69% | -7.20% | +0.44% | -36.97% | +7.27% |
How might Ms. Jaswani's specific expertise in ROC filings and regulatory processes impact Alpa Laboratories' compliance efficiency and risk management in the coming fiscal year?
Given the absence of a defined term for this Key Managerial Personnel appointment, what are the expectations regarding performance reviews and potential contract renewals?
Does this appointment signal any upcoming changes in Alpa Laboratories' corporate governance structure or strategic compliance initiatives?


































